The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
Open accessAbstract
Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome–coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome–CoV and Middle East respiratory syndrome (MERS–CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS–CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS–CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i , the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3′–5′ exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Self-citationA Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Self-citationTherapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Self-citationAgostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Self-citationIdentification of four conserved motifs among the RNA-dependent polymerase encoding elements.
Poch, O., Sauvaget, I., Delarue, M., & Tordo, N. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08565.x · Cited by 1,202
Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
Kirchdoerfer, R. N., & Ward, A. B. (2019) · Nature Communications · doi:10.1038/s41467-019-10280-3 · Cited by 896
de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D., Cihlar, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 887
de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 736
Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01594 · Cited by 643
Self-citation
Research works printed but not linked: 1
- Tchesnokov, 2008, Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase, J. Biol. Chem, 283, 34218, 10.1074/jbc.M806797200 · doi:10.1074/jbc.m806797200
Cited by
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
COVID-19 and cardiovascular disease
Clerkin, K. J., Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., Jain, S. S., Burkhoff, D., Kumaraiah, D., Rabbani, L., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046941 · Cited by 1,738
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
The epidemiology, diagnosis and treatment of COVID-19
Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y., & Li, Y. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105955 · Cited by 1,014
Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., Feng, J. Y., Porter, D. P., & Götte, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013679 · Cited by 985
Self-citationEastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., & Hall, M. D. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00489 · Cited by 953
Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review
Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., & Smith, L. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17082690 · Cited by 822
Structure of replicating SARS-CoV-2 polymerase
Hillen, H. S., Kokic, G., Farnung, L., Dienemann, C., Tegunov, D., & Cramer, P. (2020) · Nature · doi:10.1038/s41586-020-2368-8 · Cited by 790
COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment
Parasher, A. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138577 · Cited by 776
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Kabinger, F., Stiller, C., Schmitzová, J., Dienemann, C., Kokic, G., Hillen, H. S., Höbartner, C., & Cramer, P. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00651-0 · Cited by 750
COVID-19: Immunology and treatment options
Felsenstein, S., Herbert, J. A., McNamara, P. S., & Hedrich, C. M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108448 · Cited by 669
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
Kokic, G., Hillen, H. S., Tegunov, D., Dienemann, C., Seitz, F., Schmitzova, J., Farnung, L., Siewert, A., Höbartner, C., & Cramer, P. (2021) · Nature Communications · doi:10.1038/s41467-020-20542-0 · Cited by 603
Candidate drugs against SARS-CoV-2 and COVID-19
McKee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104859 · Cited by 562
Ogando, N. S., Dalebout, T. J., Zevenhoven-Dobbe, J. C., Limpens, R. W. A. L., van der Meer, Y., Caly, L., Druce, J., de Vries, J. J. C., Kikkert, M., Bárcena, M., et al. (2020) · Journal of General Virology · doi:10.1099/jgv.0.001453 · Cited by 551
Malone, B., Urakova, N., Snijder, E. J., & Campbell, E. A. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00432-z · Cited by 530
Romano, M., Ruggiero, A., Squeglia, F., Maga, G., & Berisio, R. (2020) · Cells · doi:10.3390/cells9051267 · Cited by 527
The molecular virology of coronaviruses
Hartenian, E., Nandakumar, D., Lari, A., Ly, M., Tucker, J. M., & Glaunsinger, B. A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.013930 · Cited by 525
Ton, A., Gentile, F., Hsing, M., Ban, F., & Cherkasov, A. (2020) · Molecular Informatics · doi:10.1002/minf.202000028 · Cited by 517
Pruijssers, A. J., George, A. S., Schäfer, A., Leist, S. R., Gralinksi, L. E., Dinnon, K. H., Yount, B. L., Agostini, M. L., Stevens, L. J., Chappell, J. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107940 · Cited by 510
Self-citationRecent Developments on Therapeutic and Diagnostic Approaches for COVID-19
Majumder, J., & Minko, T. (2021) · The AAPS Journal · doi:10.1208/s12248-020-00532-2 · Cited by 505
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 480
Coronaviruses and SARS-CoV-2: A Brief Overview
Ludwig, S., & Zarbock, A. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004845 · Cited by 376
Shannon, A., Le, N. T.-T., Selisko, B., Eydoux, C., Alvarez, K., Guillemot, J.-C., Decroly, E., Peersen, O., Ferron, F., & Canard, B. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104793 · Cited by 352
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
McCreary, E. K., & Pogue, J. M. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa105 · Cited by 334
COVID-19 Pandemic: Prevention and Protection Measures to Be Adopted at the Workplace
Cirrincione, L., Plescia, F., Ledda, C., Rapisarda, V., Martorana, D., Moldovan, R. E., Theodoridou, K., & Cannizzaro, E. (2020) · Sustainability · doi:10.3390/su12093603 · Cited by 334
Atri, D., Siddiqi, H. K., Lang, J. P., Nauffal, V., Morrow, D. A., & Bohula, E. A. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.04.002 · Cited by 321
Cao, Y.-C., Deng, Q.-X., & Dai, S.-X. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101647 · Cited by 320
SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Uddin, M., Mustafa, F., Rizvi, T. A., Loney, T., Al Suwaidi, H., Al-Marzouqi, A. H. H., Kamal Eldin, A., Alsabeeha, N., Adrian, T. E., Stefanini, C., et al. (2020) · Viruses · doi:10.3390/v12050526 · Cited by 319
Coronavirus Disease (COVID-19): A primer for emergency physicians
Chavez, S., Long, B., Koyfman, A., & Liang, S. Y. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.03.036 · Cited by 311
Ge, Y., Tian, T., Huang, S., Wan, F., Li, J., Li, S., Wang, X., Yang, H., Hong, L., Wu, N., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00568-6 · Cited by 300
Shannon, A., Selisko, B., Le, N.-T.-T., Huchting, J., Touret, F., Piorkowski, G., Fattorini, V., Ferron, F., Decroly, E., Meier, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18463-z · Cited by 296
The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase
Lung, J., Lin, Y., Yang, Y., Chou, Y., Shu, L., Cheng, Y., Liu, H. T., & Wu, C. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25761 · Cited by 295
Remdesivir against COVID-19 and Other Viral Diseases
Malin, J. J., Suárez, I., Priesner, V., Fätkenheuer, G., & Rybniker, J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00162-20 · Cited by 295
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
Gordon, C. J., Tchesnokov, E. P., Schinazi, R. F., & Götte, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100770 · Cited by 293
Self-citationNucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19
Chien, M., Anderson, T. K., Jockusch, S., Tao, C., Li, X., Kumar, S., Russo, J. J., Kirchdoerfer, R. N., & Ju, J. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00392 · Cited by 286
Lamb, Y. N. (2020) · Drugs · doi:10.1007/s40265-020-01378-w · Cited by 284
Paital, B., Das, K., & Parida, S. K. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138914 · Cited by 281
Architecture and self‐assembly of the SARS‐CoV ‐2 nucleocapsid protein
Ye, Q., West, A. M. V., Silletti, S., & Corbett, K. D. (2020) · Protein Science · doi:10.1002/pro.3909 · Cited by 277
The novel zoonotic COVID-19 pandemic: An expected global health concern
Contini, C., Di Nuzzo, M., Barp, N., Bonazza, A., De Giorgio, R., Tognon, M., & Rubino, S. (2020) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.12671 · Cited by 272
Updated Approaches against SARS-CoV-2
Li, H., Zhou, Y., Zhang, M., Wang, H., Zhao, Q., & Liu, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00483-20 · Cited by 258
Humeniuk, R., Mathias, A., Cao, H., Osinusi, A., Shen, G., Chng, E., Ling, J., Vu, A., & German, P. (2020) · Clinical and Translational Science · doi:10.1111/cts.12840 · Cited by 257
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Tompa, D. R., Immanuel, A., Srikanth, S., & Kadhirvel, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.076 · Cited by 257
A critical overview of computational approaches employed for COVID-19 drug discovery
Muratov, E. N., Amaro, R., Andrade, C. H., Brown, N., Ekins, S., Fourches, D., Isayev, O., Kozakov, D., Medina-Franco, J. L., Merz, K. M., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01065k · Cited by 206
Microstructure, pathophysiology, and potential therapeutics of COVID‐19: A comprehensive review
Singh, S. P., Pritam, M., Pandey, B., & Yadav, T. P. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26254 · Cited by 166
“viruses, including Ebola could be effective in both prophylaxis and treatment of 2019nCoV infections.(168) This drug was positively tested in a rhesus macaque model of MERSCoV infection.”
BackgroundA Comprehensive Review About SARS-CoV-2
Haque, S. M., Ashwaq, O., Sarief, A., & Azad John Mohamed, A. K. (2020) · Future Virology · doi:10.2217/fvl-2020-0124 · Cited by 121
“Remdesivir, a novel antiviral nucleotide analog, was successfully used in the USA with a patient infected with the SARS-CoV-2 virus [178,179].”
MethodVerma, A. K., & Aggarwal, R. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13812 · Cited by 54
Zhang, L., Zhang, D., Wang, X., Yuan, C., Li, Y., Jia, X., Gao, X., Yen, H.-L., Cheung, P. P.-H., & Huang, X. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d0cp05948j · Cited by 52
Metadata
- Authors
- Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 295
- Issue
- 15
- Pages
- 4773-4779
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W3007969569
- Cited by
- 850
- References
- 25
- FWCI
- 23.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 227 d)
- Funders
- Gouvernement du Canada | Canadian Institutes of Health Research (159507)
- Alberta Ministry of Economic Development, Trade, and Tourism by the Major Innovation Fund Program (AMR-One Health Consortium)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.